 |
|
|
| |
Phase 1b Efficacy and Safety of NVR 3-778, a First-In-Class HBV Core Inhibitor, in HBeAg-Positive Patients with Chronic HBV Infection
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
M-F Yuen1, DJ Kim2, F Weilert3, H L-Y Chan4, J Lalezari5, SG Hwang6, T Nguyen7, S Liaw8, N Brown8, K Klumpp8, L Flores8, G Hartman8, EJ Gane9
1Queen Mary Hospital, Univ. of Hong Kong, Hong Kong; 2Hallym University, ChuncheonSacred Heart Hospital, Gangwon-do, Republic of Korea; 3Waikato Hospital, Hamilton, New Zealand; 4Prince of Wales Hospital, Chinese Univ. of Hong Kong, Hong Kong; 5Quest Clinical Research, San Francisco, CA, USA; 6CHA BundangMedical Center, Gyeonggi-do, Republic of Korea; 7Research and Education, Inc., San Diego, CA, USA; 8Novira Therapeutics, Doylestown, PA, USA; 9Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
